Aurinia Pharmaceuticals Inc. AUPH
16.56 USD +0.42 (+2.60%)
At closeNov 3, 2026, 4:01 PM EST
16.56 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
16.13 Day range 16.73
13.33 52-week range 19.25
- YTD
- +3.82%
- 1 year
- +25.74%
Analyst view
Consensus: buy
Buy
Price target (mean) 18.29 +10.4% upside
Now 16.56
- Target (low)
- 16.00
- Target (mean)
- 18.29
- Target (high)
- 21.00
Ratings (0m) 7 5 buy · 2 hold · 0 sell
- Strong buy0
- Buy5
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.214 | 0.17 – 0.24 | 1.53 | -86.0% | 85.57M | +11.0% | 5 |
| Next quarter | 0.19 | 0.17 – 0.21 | 0.25 | -24.0% | 82.95M | +6.8% | 2 |
| Current year | 0.97 | 0.93 – 1.00 | 2.07 | -53.1% | 330.19M | +16.7% | 5 |
| Next year | 1.16 | 0.68 – 1.63 | 0.97 | +19.6% | 388.73M | +17.7% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Oct 21, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 7, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Dec 3, 2025 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Nov 7, 2025 | Jefferies | Upgrade | Hold | Buy |
| Nov 5, 2025 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Aug 1, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 16, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 9, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 6, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 1, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 23, 2024 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Feb 22, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 16, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 22, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 7, 2023 | HC Wainwright& Co. | Maintained | Buy | Buy |
| Jul 6, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| May 3, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Feb 23, 2023 | RBC Capital | Reiterated | — | Outperform |
| Jan 4, 2023 | RBC Capital | Maintained | — | Outperform |
| Nov 7, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 4, 2022 | RBC Capital | Maintained | — | Outperform |
| Nov 4, 2022 | Oppenheimer | Downgrade | Outperform | Perform |
| Nov 4, 2022 | SVB Leerink | Maintained | — | Outperform |
| Aug 9, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 8, 2022 | Oppenheimer | Maintained | — | Outperform |
| May 5, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Apr 28, 2022 | RBC Capital | Maintained | — | Outperform |
| Mar 8, 2022 | SVB Leerink | Maintained | — | Outperform |
| Mar 1, 2022 | RBC Capital | Maintained | — | Outperform |
